Group With Hedge Fund Ties Denied Review Of Enbrel Patent
The Patent Trial and Appeal Board on Friday declined to institute a review of claims of Hoffman-LaRoche's patent related to blockbuster immunosuppressant Enbrel, finding that a group with ties to hedge...To view the full article, register now.
Already a subscriber? Click here to view full article